IMA — ImageneBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1835579 ·
Last close
$5.62
Market Cap
$63.80M
52W High
$6.30
52W Low
$5.28
ADV30
10,729
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -11,784,000 | -10,178,000 | 152,045,000 | 94,677,000 | 9,971,000 |
| Mar 2026 | 0 | — | -12,079,000 | -10,619,000 | 136,682,000 | 76,048,000 | 13,355,000 |
| Dec 2025 | 0 | — | -8,504,000 | -6,908,000 | 152,976,000 | 94,532,000 | 19,837,000 |
| Sep 2025 | 0 | — | -26,594,000 | -24,779,000 | 160,878,000 | 103,162,000 | 21,046,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,586,000
Investing CF
$-6,600,000
Financing CF
$147,228,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-250,850,000
Inventory
—
Receivables
$1,296,000
ST Investments
$41,476,000
EBIT TTM
$-58,961,000
Pretax Income TTM
$-52,808,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-58,366,500
Free Cash Flow
$-23,211,624
Enterprise Value
$-71,694,480
Total Cash
$136,152,992
Total Debt
$1,912,000
Shares Out
11,351,456
Trailing EPS
$-4.73
Book Value
$12.60
ROE
-82.7%
ROA
-43.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 800,000 | -48,451,000 | -45,349,000 | 152,976,000 | 19,837,000 | — | -47,844,000 |
| Dec 2024 | 3,500,000 | -37,000,000 | -36,568,000 | 15,922,000 | 176,487,000 | — | -21,319,000 |
| Dec 2023 | 7,962,000 | -21,925,000 | -21,148,000 | 31,245,000 | 157,353,000 | — | -18,233,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $64.51M | $6.95 | — |
| INMB | Inmune Bio, Inc. | $65.50M | $2.36 | — |
| INKT | MiNK Therapeutics, Inc. | $60.32M | $11.82 | — |
| ENZN | Viskase Holdings, Inc. | $67.50M | $4.71 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $68.69M | $19.99 | — |
News headlines (Yahoo Finance, 1h cache)
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-17 20:30 · Yahoo
ImageneBio Reports Second Quarter 2026 Financial Results
2026-08-05 12:00 · Yahoo
ImageneBio Appoints Matt Robbins as General Counsel
2026-07-07 11:00 · Yahoo
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
2026-05-27 20:30 · Yahoo
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
2026-05-07 20:05 · Yahoo
ImageneBio Announces $30 Million Private Placement
2026-04-13 11:00 · Yahoo
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
2026-03-24 12:35 · Yahoo
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2026-03-10 12:00 · Yahoo
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
2026-02-10 12:00 · Yahoo
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
2025-12-31 11:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.